Article
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2024
Felip E, Cho B C, Gutiérrez V, Alip A, Besse B, Lu S, Spira A I, Girard N, Califano R, Gadgeel S M, Yang J C-H, Yamamoto S, Azuma K, Kim Y J, Lee K-H, Danchaivijitr P, Ferreira C G, Cheng Y, Sendur M A N, Chang G-C, Wang C-C, Prabhash K, Shinno Y, Stroyakovskiy D, Paz-Ares L, Rodriguez-Cid J R, Martin C, Campelo M R G, Hayashi H, Nguyen D, Tomasini P, Gottfried M, Dooms C, Passaro A, Schuler M, Gelatti A C Z, Owen S, Perdrizet K, Ou S-H I, Curtin J C, Zhang J, Gormley M, Sun T, Panchal A, Ennis M, Fennema E, Daksh M, Sethi S, Bauml J M, Lee S-H
Abstract excerpt
BACKGROUND: Amivantamab-lazertinib significantly prolonged progression-free survival (PFS) versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer [NSCLC; hazard ratio (HR) 0.70; P < 0.001], including those with a history of brain metastases (HR 0.69). Patients with TP53 co-mutations, detectable circulating tumor DNA (ctDNA), baseline liver...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.